YOLFTbeta
XORTX Therapeutics Inc

XORTX Therapeutics Inc

XRTX · NASDAQ · Healthcare / Biotechnology

1.10USD+0.18 (+19.57%)

Price History

Full chart

Market Stats

Previous Close0.92
Open0.9097
Day Range0.8151 – 1.20
52-Week Range1.59 – 7.05
Volume1.60M
Market Cap3.09M
P/E (TTM)0.00
Forward P/E0.96
EPS-2.63
Dividend Yield0.00%
Beta0.44
50-Day Avg2.07
200-Day Avg2.31

About

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Allen Warren Davidoff Ph.D.
  • Employees0
  • Headquarters3710 - 33rd Street NW, Calgary, AB, Canada, T2L 2M1, USA
  • Websitehttps://www.xortx.com

Leadership

  • Dr. Allen Warren Davidoff Ph.D.Founder, Co-CEO, President & Director · b. 1960
  • Dr. Michael Scott Bumby D.V.M., M.B.A.Chief Financial Officer · b. 1964
  • Dr. Stephen Haworth M.D., MRCPChief Medical Officer · b. 1950
  • Dr. Stacy Evans M.B.A., M.D.Chief Business Officer · b. 1974
  • Mr. Mika GrassoCo-CEO & Director · b. 1998
  • Nick RigopulosDirector of Communications
  • Dr. David Sans M.B.A., Ph.D.Director of Corporate Development · b. 1970
  • Dr. David MacDonald Ph.D.Consultant of Clinical Operations · b. 1963
  • Ms. Charlotte MayCorporate Secretary

Financials

Income Statement

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---000000000
Cost of Revenue----19.32K19.90K20.44K18.02K74.61K141.96K111.64K114.08K
Gross Profit-----19.32K-19.90K-20.44K-18.02K-74.61K-141.96K-111.64K-114.08K
Operating Expense----1.05M546.07K1.06M3.66M12.36M5.90M3.81M3.14M
Operating Income-36.92K-243.94K-389.31K-427.11K-1.07M-565.97K-1.08M-3.68M-12.43M-6.05M-3.92M-3.26M
EBITDA-36.92K-243.94K-389.31K-427.11K-1.07M-572.47K-1.08M-2.90M-12.49M-5.91M-3.81M-3.14M
Net Income-36.92K-279.31K-414.83K-474.20K-3.78M-629.58K-1.28M-1.66M-10.45M-2.16M-3.15M-2.66M
R&D---66.37K342.25K39.90K277.45K856.82K9.16M2.42M175.00K574.93K
Interest Expense--8.63K15.46K22.30K38.23K12.67K5.63K0---

Balance Sheet

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets143.94K203.44K282.46K490.60K1.27M1.09M2.29M17.38M12.37M5.47M4.09M2.68M
Total Liabilities48.08K6.17K599.52K1.15M943.70K1.30M1.03M4.18M5.38M825.94K757.99K597.98K
Total Equity95.85K197.27K-317.06K-654.63K321.54K-211.72K1.26M13.20M7.00M4.64M3.34M2.08M
Cash609.0327.01K166.49K49.26K190.91K58.61K171.27K14.87M10.43M3.45M2.47M862.94K
Total Debt--124.13K216.67K43.26K50.81K--77.60K11.51K38.78K37.22K
Net Debt-609-27.01K-42.36K167.42K-147.65K-7.80K-171.27K-14.87M-10.36M-3.44M-2.43M-825.72K

Cash Flow

Currency: USD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-85.36K-128.57K-107.78K91.17K-920.56K-249.58K-728.40K-4.80M-8.17M-6.58M-3.68M-2.82M
Investing Cash Flow-24.11K-39.11K-24.56K-179.70K-154.81K-5.39K-14.35K-31.81K-45.70K-46.36K-38.92K-300.12K
Financing Cash Flow109.19K194.14K115.00K133.70K1.91M55.21K855.41K19.37M3.91M-361.04K2.78M1.45M
Capital Expenditure24.11K39.11K3.79K9.93K30.16K5.39K11.25K31.81K45.70K46.36K38.92K3
Free Cash Flow-109.47K-167.69K-145.12K62.58K-1.17M-196.45K-742.75K-4.83M-9.01M-6.63M-3.72M-2.82M
FCF to OCF128.25%130.42%134.64%68.63%127.32%78.71%101.97%100.66%110.33%100.70%101.06%100.00%

Earnings

Report DateMar 31, 2011Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Jun 1, 2020Aug 31, 2020Nov 30, 2020Dec 31, 2020Apr 27, 2021Aug 27, 2021Nov 29, 2021May 12, 2022Aug 11, 2022Nov 10, 2022Mar 31, 2023May 14, 2023Aug 13, 2023Nov 14, 2023Dec 31, 2023May 15, 2024Aug 14, 2024Nov 12, 2024Mar 25, 2025May 15, 2025Aug 15, 2025Nov 14, 2025Feb 26, 2026May 18, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate0.13------------0.07-9.90-11.25-0.16-0.27-10.35-11.25-0.19-0.81-4.21-4.61--2.08---1.58-1.58---
EPS Actual0.15-0.94-0.97-0.98-0.84-1.21-0.00-0.04-0.05-2.26-0.21-0.02-0.70-12.60-11.67-0.17-0.20-4.77-4.23-0.67-0.64-2.96-3.44-0.20-1.17-0.19-0.19-1.02-0.09-0.58-1.05-
Surprise15.38%------------863.57%-27.27%-3.73%-3.96%25.93%53.91%62.40%-252.63%21.96%29.69%25.38%-43.75%--35.44%94.30%---
Timing------After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours--After-hoursAfter-hours---

Key Statistics & Ratios

Market Cap3.09M
Enterprise Value2.85M
Trailing P/E0.00
Forward P/E0.96
Price / Sales0.00
Price / Book0.56
EPS-2.63
Book Value1.50
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-2.15M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-99.24%
Return on Assets-29.85%
Shares Outstanding1.82M
Shares Float1.79M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 14.04
  • Strong Buy
    1

Ownership Breakdown

Institutions
10.49%
Insiders
1.53%
Retail / Other
87.98%

Top Institutional Holders

  • Citadel Advisors Llc
    23.12K1.27%
  • Kingsview Wealth Management, LLC
    15.00K0.83%
  • Hartland & Co
    2770.02%
  • NATIONAL BANK OF CANADA /FI/
    1620.01%
  • DRW Securities, LLC
    00.00%
  • Royal Bank of Canada
    00.00%
  • Baader Bank INC
    00.00%
  • TWO SIGMA SECURITIES, LLC
    00.00%
  • UBS Group AG
    00.00%

Stock Splits

  • Apr 6, 20261:5
  • Nov 14, 20231:9